Comparison of Survival Outcomes Among Patients With Breast Cancer With Distant vs Ipsilateral Supraclavicular Lymph Node Metastases

Authors:

Abstract
Breast cancer is a common malignant disease worldwide. The incidence of synchronous distant metastases in patients with newly diagnosed breast cancer is approximately 3% to 8%.1-3 Unfortunately, stage IV breast cancer is an incurable disease with a poor prognosis. Patients with central nervous system or liver metastases show poorer survival than patients with other metastasis sites, including bone, the lungs, and distant lymph nodes.4,5 Systemic therapy is the main treatment for stage IV breast cancer to prolong patient survival and palliate the symptoms. However, with advances in systemic therapies, highly selected stage IV breast cancer (eg, patients with bone or distant lymph node metastases [DLNM]) may be potentially curable, especially for limited metastatic burden and favorable site cases.6-8 Understanding the characteristics of breast cancer metastasis is necessary to select the appropriate patients for precise and aggressive therapy.

This publication has 26 references indexed in Scilit: